How the unfolding of notable infringement claim could alter commercial approaches for players in wider CBD treatment field.
David Knight
Advertisement
Articles by David Knight
Advertisement
Latest Updated Articles
Commercializing Cannabis and Patent LitigationPublished: February 10th 2021 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
2
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
3
Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER
4
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
5
